查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
NGS(RNA-Sep)RNA测序全球市场：按产品/服务（样品製备,平台/耗材,服务,数据分析）,技术（SBS,SMRT,纳米孔）,应用（从头,表观遗传）典型,小RNA）,用户,地区预测到2027
市场调查报告书
商品编码
1270837

NGS(RNA-Sep)RNA测序全球市场：按产品/服务（样品製备,平台/耗材,服务,数据分析）,技术（SBS,SMRT,纳米孔）,应用（从头,表观遗传）典型,小RNA）,用户,地区预测到2027

NGS-based RNA-sequencing Market by Product & Services (Sample Preparation, Platforms & Consumables, Services, Data Analysis), Technology (SBS, SMRT, Nanopore), Application (De Novo, Epigenetics, small RNA), End-User, Region - Global Forecast to 2027
出版日期: | 出版商: MarketsandMarkets | 英文 202 Pages | 订单完成后即时交付

价格
简介目录

全球 NGS RNA 测序 (RNA-Sep) 市场规模到 2027 年将达到 55 亿美元，高于 2022 年的 25 亿美元，复合年增长率为 17.2% 在预测期内预计将增长。

NGS RNA 测序 (RNA-Sep) 市场的增长主要是由于 RNA 测序相对于传统技术的优势、基因组测序成本的下降、政府增加对基因组学项目的资助以及涉及 RNA 测序的研究不断扩大., 由于癌症患者数量的不断增加，NGS在癌症研究中的应用不断扩大，以及个性化医疗的快速增长。 另一方面，合格专业人员短缺、新兴国家的最终用户预算限制以及诊断测试中的标准化问题预计将限制市场增长。

“预计纳米孔测序领域在预测期内将以显着的复合年增长率增长”

按技术划分，NGS RNA 测序 (RNA-Sep) 市场分为 SBS、离子半导体测序、SMRT 测序和纳米孔测序。 纳米孔测序部分预计将在 2022 年至 2027 年实现最高的复合年增长率。 纳米孔测序是唯一具有直接 RNA 测序能力的测序技术。 与其他新一代测序技术相比，纳米孔测序是对天然DNA和RNA进行单分子测序，可以检测单个核甘酸的修饰，因此引物覆盖了16S基因全长甚至整个核醣体操纵子。由于实时靶向测序、长读取长度、全长 cDNA 读取和结构变异的稳健检测等优势，用户采用率正在增加。

“从应用来看，表达谱分析细分市场将在 2021 年占据主导地位”

按应用，NGS RNA 测序 (RNA-Sep) 市场分为表达谱分析、小 RNA 测序、从头转录组组装和变异检出转录组表观遗传学。 到 2021 年，表达谱分析部分将占据 NGS (RNA-Sep) RNA 测序市场的最大份额。 代谢疾病、多发性硬化症等疾病的流行率不断上升，预计将推动对錶达谱分析的需求。

“北美将在 2021 年主导市场”

NGS RNA 测序 (RNA-Sep) 市场按地区划分为北美、欧洲、亚太地区、拉丁美洲以及中东和非洲。 到 2021 年，北美将占据 NGS（RNA-Sep）市场 RNA 测序的主要份额。 北美以政府支持、RNA 测序产品的进步、目标疾病的流行率增加、对癌症和罕见遗传病的研究增加以及主要参与者在该地区的强大存在为主导。占据了重要的市场份额。 然而，由于对研发的高度重视、NGS 产品和服务的成本降低以及主要市场参与者越来越关注加强其在亚太地区的影响力，亚太市场在预测期内将继续增长。预计将以最高的复合年增长率增长。

内容

第一章介绍

第二章研究方法论

第 3 章执行摘要

第 4 章重要注意事项

第 5 章市场概述

  • 介绍
  • 市场动态
    • 司机
    • 约束因素
    • 机会
    • 任务

第 6 章 NGS RNA 测序（RNA-Sep）市场：按产品和服务分类

  • 介绍
  • RNA 测序 (RNA-Sep) 平台和耗材
  • 样品製备产品
  • RNA 测序 (RNA-Sep) 服务
  • 数据分析/存储/管理

第 7 章 NGS RNA 测序 (RNA-Sep) 市场：按技术分类

  • 介绍
  • SBS
  • 离子半导体测序
  • SMRT序列
  • 纳米孔测序

第 8 章 NGS RNA 测序 (RNA-Sep) 市场：按应用

  • 介绍
  • 表达谱分析
  • 小RNA测序（RNA-Sep）
  • 从头转录组组装
  • 变异调用转录组表观遗传学

第 9 章 NGS RNA 测序（RNA-Sep）市场：最终用户

  • 介绍
  • 研究和学术
  • 医院和诊所
  • 製药和生物技术公司
  • 其他

第 10 章 NGS RNA 测序（RNA-Sep）市场：按地区

  • 介绍
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中东和非洲

第11章竞争格局

  • 概览
  • 主要公司战略/领先公司
  • 市场份额分析
  • 顶级市场公司的收入份额分析
  • 竞争领导力映射
  • 竞争场景

第12章公司简介

  • 主要公司
    • ILLUMINA, INC.
    • QIAGEN N.V.
    • PERKINELMER, INC.
    • EUROFINS SCIENTIFIC
    • OXFORD NANOPORE TECHNOLOGIES
    • AGILENT TECHNOLOGIES, INC.
    • BGI GROUP
    • GENEWIZ（PART OF BROOKS AUTOMATION）
    • HAMILTON COMPANY
    • NUGEN TECHNOLOGIES（PART OF TECAN TRADING AG）
    • PSOMAGEN（FORMERLY KNOWN AS MACROGEN）
    • F. HOFFMANN-LA ROCHE AG
    • THERMO FISHER SCIENTIFIC, INC.
    • TAKARA BIO, INC.
    • PACIFIC BIOSCIENCES
  • 其他企业
    • ZYMO RESEARCH
    • LUCIGEN CORPORATION
    • GENOTYPIC TECHNOLOGY
    • OXFORD GENE TECHNOLOGY（PART OF SYSMEX）
    • BECTON, DICKINSON AND COMPANY

第13章 附录

简介目录
Product Code: BT 5297

The global NGS-based RNA-sequencing market is projected to reach USD 5.5 billion by 2027 from USD 2.5 billion in 2022, at a CAGR of 17.2% during the forecast period. Growth in the NGS-based RNA-sequencing market is mainly driven by the advantages of RNA sequencing over conventional technologies, the decreasing cost of genome sequencing, increasing government funding to support genomics projects, growing research involving RNA sequencing, growing cancer cases, the increasing application of NGS in cancer research, and rapid growth in personalized medicine. On the other hand, a lack of qualified specialists, end-user budget constraints in developing countries, and standardization concerns in diagnostic testing are expected to limit the market growth.

"Nanopore sequencing segment is anticipated to grow at substantial CAGR during the forecast period."

Based on technology, the NGS-based RNA-sequencing market has been segmented into sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, and nanopore sequencing. The nanopore sequencing segment is projected to register the highest CAGR from 2022 to 2027. Nanopore sequencing is the only sequencing technology with direct RNA-sequencing capabilities. The adoption of nanopore sequencing is increasing among end users due to its benefits as compared to other next-generation sequencing technologies, such as single-molecule sequencing of native DNA and RNA capable of detecting modifications in individual nucleotides allowing primers to cover the whole length of the 16S gene or even whole ribosomal operons, real-time targeted sequencing, large read lengths and full-length cDNA read, and reliable detection of structural variants.

"Expression profiling analysis applications segment dominated the market in 2021."

On the basis of application, the NGS-based RNA-sequencing market is segmented into expression profiling analysis, small RNA sequencing, de novo transcriptome assembly, and variant calling & transcriptome epigenetics. In 2021, the expression profiling analysis segment accounted for the largest share of the NGS-based RNA-sequencing market. The increasing prevalence of metabolic disorders, multiple sclerosis, and other diseases are expected to propel the demand for expression profiling analysis.

"North America held the dominant share of the market in 2021."

Geographically, the NGS-based RNA-sequencing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the major share of the NGS-based RNA-sequencing market. North America held the dominant share owing to the availability of government support, advancements in RNA sequencing products, the growing prevalence of target diseases, growing research on cancer and inherited rare diseases, and the strong presence of key players in the region. However, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period, owing to a significant focus on R&D, the decreasing costs of NGS products and services, and the increasing focus of major market players on strengthening their presence in the Asia Pacific.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type - Tier 1: 45%, Tier 2: 34%, Tier 3: 21%
  • By Designation - C-level: 47.0%, D-level: 33.0%, and Others: 20.0%
  • By Region - North America: 35%, Europe: 32%, Asia Pacific: 25%, Latin America: 6%, and the Middle East & Africa: 2%

List of Companies Profiled in the Report

    • Illumina, Inc. (US)
    • Thermo Fisher Scientific, Inc. (US)
    • PerkinElmer, Inc. (US)
    • QIAGEN N.V. (Netherlands)
    • Eurofins Scientific (UK)
    • Oxford Nanopore Technologies (UK)
    • Agilent Technologies, Inc. (US)
    • BGI Group (China)
    • GENEWIZ (US)
    • Hamilton Company (US)
    • NuGEN Technologies (US)
    • Psomagen, Inc. (South Korea)
    • F. Hoffmann-La Roche AG (Switzerland)
    • Takara Bio, Inc. (Japan)
    • Pacific Biosciences (US)
    • Zymo Research Corporation (US)
    • Lucigen Corporation (US)
    • Genotypic Technology (India)
    • Oxford Gene Technology (UK)
    • Becton, Dickinson and Company (US)

Research Coverage:

This report provides a detailed picture of the global NGS-based RNA-sequencing market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, application, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total NGS-based RNA-sequencing market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on NGS-based RNA-sequencing offered by the top 20 players in the NGS-based RNA-sequencing market. The report analyses the NGS-based RNA-sequencing market by product & service, technology, application, end user, and region.
  • Market Development: Comprehensive information about beneficial emerging markets. The report analyzes the markets for various NGS-based RNA-sequencing products and services across key geographic regions.
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the NGS-based RNA-sequencing market.
  • Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the NGS-based RNA-sequencing market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 REGIONAL SCOPE
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY RESEARCH
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY RESEARCH
      • 2.1.2.1 Key data from primary sources
    • FIGURE 2 BREAKDOWN OF PRIMARIES
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
    • 2.2.1 PRODUCT-BASED MARKET ESTIMATION
    • FIGURE 4 PRODUCT-BASED MARKET ESTIMATION
    • 2.2.2 APPLICATION-BASED MARKET ESTIMATION
    • FIGURE 5 APPLICATION-BASED MARKET ESTIMATION
  • 2.3 PRIMARY RESEARCH VALIDATION
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION
  • 2.5 STUDY ASSUMPTIONS
    • FIGURE 7 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

    • FIGURE 8 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 9 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    • FIGURE 10 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 11 NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 REGIONAL SNAPSHOT OF NGS-BASED RNA-SEQUENCING MARKET

4 PREMIUM INSIGHTS

  • 4.1 NGS-BASED RNA-SEQUENCING MARKET OVERVIEW
    • FIGURE 13 GROWING RESEARCH ACTIVITIES INVOLVING RNA-SEQUENCING TO DRIVE MARKET
  • 4.2 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY END USER AND COUNTRY (2021)
    • FIGURE 14 CHINA TO DOMINATE ASIA PACIFIC MARKET IN 2021
  • 4.3 GEOGRAPHICAL SNAPSHOT OF NGS-BASED RNA-SEQUENCING MARKET
    • FIGURE 15 CHINA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 4.4 NGS-BASED RNA-SEQUENCING MARKET, BY REGION
    • FIGURE 16 NORTH AMERICA TO DOMINATE NGS-BASED RNA-SEQUENCING MARKET IN 2027

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 17 NGS-BASED RNA-SEQUENCING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Decreasing costs of genome sequencing
    • FIGURE 18 COST OF HUMAN WHOLE-GENOME SEQUENCING, 2001-2021
      • 5.2.1.2 Advantages of RNA-sequencing over conventional technologies
      • 5.2.1.3 Increasing government funding to support genomics projects
      • 5.2.1.4 Growing research involving RNA-sequencing
      • 5.2.1.5 Rising cancer cases and increasing applications of NGS in cancer research
    • TABLE 1 CANCER INCIDENCE, 2020 VS. 2040
      • 5.2.1.6 Rapid growth in personalized medicine adoption
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Lack of qualified specialists
      • 5.2.2.2 End-user budget constraints in developing countries
      • 5.2.2.3 Standardization concerns of RNA-sequencing in diagnostic testing
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Adoption of blockchain technology and cloud computing
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Storage and interpretation of sequencing data
      • 5.2.4.2 Analysis of RNA-sequencing data to detect novel transcripts
      • 5.2.4.3 Ethical issues and challenges in testing procedure

6 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 2 NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
  • 6.2 RNA-SEQUENCING PLATFORMS & CONSUMABLES
    • 6.2.1 INCREASING AVAILABILITY OF PLATFORMS AND GROWING CONSUMABLE USAGE TO ENSURE GROWTH
    • TABLE 3 RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 4 NORTH AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 5 EUROPE: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 6 ASIA PACIFIC: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 7 LATIN AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 6.3 SAMPLE PREPARATION PRODUCTS
    • 6.3.1 SAMPLE PREPARATION TO BE FIRST STEP OF NGS WORKFLOW
    • TABLE 8 SAMPLE PREPARATION PRODUCTS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 9 NORTH AMERICA: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 10 EUROPE: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 11 ASIA PACIFIC: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 12 LATIN AMERICA: SAMPLE PREPARATION PRODUCTS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.3.2 SAMPLE PREPARATION PRODUCTS, BY WORKFLOW
      • 6.3.2.1 Library preparation & target enrichment
      • 6.3.2.2 Quality control
    • 6.3.3 SAMPLE PREPARATION PRODUCTS, BY METHOD
      • 6.3.3.1 Manual sample preparation
      • 6.3.3.2 Microfluidic sample preparation
      • 6.3.3.3 Robotic liquid handling sample preparation
  • 6.4 RNA-SEQUENCING SERVICES
    • 6.4.1 INCREASING ADOPTION OF ADVANCED INFRASTRUCTURE AND EXPERTISE AMONG END USERS TO DRIVE DEMAND
    • TABLE 13 RNA-SEQUENCING SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 14 NORTH AMERICA: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 15 EUROPE: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 16 ASIA PACIFIC: RNA-SEQUENCING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 17 LATIN AMERICA: RNA-SEQUENCING PLATFORMS & CONSUMABLES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.5 DATA ANALYSIS, STORAGE & MANAGEMENT
    • 6.5.1 INTEGRATION OF CLOUD COMPUTING AND BIOINFORMATICS TO PROPEL MARKET
    • TABLE 18 DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 19 NORTH AMERICA: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 20 EUROPE: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 21 ASIA PACIFIC: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 22 LATIN AMERICA: DATA ANALYSIS, STORAGE & MANAGEMENT MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

7 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 23 NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
  • 7.2 SEQUENCING BY SYNTHESIS
    • 7.2.1 SBS TECHNOLOGY TO ENABLE HIGHEST PRODUCTION OF BASE PAIRS WITHIN SHORTEST TIME
    • TABLE 24 SEQUENCING BY SYNTHESIS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 25 NORTH AMERICA: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 26 EUROPE: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 28 LATIN AMERICA: SEQUENCING BY SYNTHESIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 ION SEMICONDUCTOR SEQUENCING
    • 7.3.1 ION SEMICONDUCTOR SEQUENCING PLATFORMS TO POSSESS HIGH-THROUGHPUT CAPABILITIES
    • TABLE 29 ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 30 NORTH AMERICA: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 31 EUROPE: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 32 ASIA PACIFIC: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 33 LATIN AMERICA: ION SEMICONDUCTOR SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.4 SINGLE-MOLECULE REAL-TIME SEQUENCING
    • 7.4.1 SMRT SEQUENCING TO PRODUCE RESULTS IN SHORTER TIME AND LOWER COSTS
    • TABLE 34 SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 35 NORTH AMERICA: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 36 EUROPE: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 37 ASIA PACIFIC: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 38 LATIN AMERICA: SINGLE-MOLECULE REAL-TIME SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.5 NANOPORE SEQUENCING
    • 7.5.1 NANOPORE SEQUENCING TO POSSESS DIRECT RNA-SEQUENCING CAPABILITIES
    • TABLE 39 NANOPORE SEQUENCING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 40 NORTH AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 41 EUROPE: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 42 ASIA PACIFIC: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 43 LATIN AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

8 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 44 NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.2 EXPRESSION PROFILING ANALYSIS
    • 8.2.1 INCREASING NEED FOR IMPROVED PROGNOSIS OF PATIENTS TO PROPEL MARKET
    • TABLE 45 EXPRESSION PROFILING ANALYSIS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 46 NORTH AMERICA: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 47 EUROPE: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 48 ASIA PACIFIC: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 49 LATIN AMERICA: EXPRESSION PROFILING ANALYSIS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.3 SMALL RNA-SEQUENCING
    • 8.3.1 RISING NEED FOR ACCURATE DIAGNOSTIC ANALYSIS TO SUPPORT MARKET
    • TABLE 50 SMALL RNA-SEQUENCING MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 51 NORTH AMERICA: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 52 EUROPE: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 54 LATIN AMERICA: SMALL RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.4 DE NOVO TRANSCRIPTOME ASSEMBLY
    • 8.4.1 INCREASING CANCER CASES TO DRIVE SEGMENT
    • TABLE 55 DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 56 NORTH AMERICA: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 57 EUROPE: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 58 ASIA PACIFIC: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 59 LATIN AMERICA: DE NOVO TRANSCRIPTOME ASSEMBLY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.5 VARIANT CALLING & TRANSCRIPTOME EPIGENETICS
    • 8.5.1 COMPLICATED RNA SEQUENCE DATA ANALYSIS TO RESTRAIN SEGMENT
    • TABLE 60 VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 61 NORTH AMERICA: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 62 EUROPE: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 64 LATIN AMERICA: VARIANT CALLING & TRANSCRIPTOME EPIGENETICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

9 NGS-BASED RNA-SEQUENCING MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 65 NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.2 RESEARCH & ACADEMIA
    • 9.2.1 INCREASING COLLABORATIONS WITH NGS PLAYERS AND RISING GOVERNMENT FUNDING TO PROPEL MARKET
    • TABLE 66 NGS-BASED RNA-SEQUENCING MARKET FOR RESEARCH & ACADEMIA, BY REGION, 2020-2027 (USD MILLION)
  • 9.3 HOSPITALS & CLINICS
    • 9.3.1 INCREASING ADOPTION OF NGS SYSTEMS TO DRIVE MARKET
    • TABLE 67 NGS-BASED RNA-SEQUENCING MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020-2027 (USD MILLION)
  • 9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.4.1 CONSOLIDATION WITH NGS PLAYERS FOR TARGET THERAPIES TO PROPEL MARKET
    • TABLE 68 NGS-BASED RNA-SEQUENCING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2027 (USD MILLION)
  • 9.5 OTHER END USERS
    • TABLE 69 NGS-BASED RNA-SEQUENCING MARKET FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION)

10 NGS-BASED RNA-SEQUENCING MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 70 NGS-BASED RNA-SEQUENCING MARKET, BY REGION, 2020-2027(USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 19 NORTH AMERICA: MARKET SNAPSHOT
    • TABLE 71 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027(USD MILLION)
    • TABLE 72 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 73 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 74 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • TABLE 75 NORTH AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027(USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Favorable funding scenario and growing R&D activity to drive market
    • TABLE 76 US: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 77 US: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 78 US: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Government initiatives for genome research to boost market
    • TABLE 79 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 80 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 81 CANADA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
  • 10.3 EUROPE
    • TABLE 82 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027(USD MILLION)
    • TABLE 83 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 84 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 85 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • TABLE 86 EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027(USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Germany to dominate European market during forecast period
    • TABLE 87 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 88 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 89 GERMANY: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Strong presence of NGS organizations and their initiatives to stimulate market
    • TABLE 90 UK: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 91 UK: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 92 UK: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Growing awareness of high-throughput sequencing in genetic characterization to accelerate growth
    • TABLE 93 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 94 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 95 FRANCE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.3.4 REST OF EUROPE
    • TABLE 96 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 97 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 98 REST OF EUROPE: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 20 ASIA PACIFIC: MARKET SNAPSHOT
    • TABLE 99 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027(USD MILLION)
    • TABLE 100 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 101 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 102 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • TABLE 103 ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027(USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 Established players and favorable government initiatives to drive market
    • TABLE 104 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 105 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 106 CHINA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Growing awareness and rising incidence of genetic disorders to propel market
    • TABLE 107 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 108 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 109 JAPAN: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Rising interest of companies for collaborations to drive market
    • TABLE 110 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 111 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 112 INDIA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC
    • TABLE 113 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 114 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 115 REST OF ASIA PACIFIC: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
  • 10.5 LATIN AMERICA
    • TABLE 116 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY COUNTRY, 2020-2027(USD MILLION)
    • TABLE 117 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 118 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 119 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • TABLE 120 LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027(USD MILLION)
    • 10.5.1 BRAZIL
      • 10.5.1.1 High HIV prevalence to drive demand for NGS in research
    • TABLE 121 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 122 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 123 BRAZIL: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.5.2 MEXICO
      • 10.5.2.1 Economic growth and support for infrastructural development to propel market
    • TABLE 124 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 125 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 126 MEXICO: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • 10.5.3 REST OF LATIN AMERICA
    • TABLE 127 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 128 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 129 REST OF LATIN AMERICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 LACK OF INFRASTRUCTURE TO RESTRAIN MARKET
    • TABLE 130 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY PRODUCT & SERVICE, 2020-2027(USD MILLION)
    • TABLE 131 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY TECHNOLOGY, 2020-2027(USD MILLION)
    • TABLE 132 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY APPLICATION, 2020-2027(USD MILLION)
    • TABLE 133 MIDDLE EAST & AFRICA: NGS-BASED RNA-SEQUENCING MARKET, BY END USER, 2020-2027(USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • FIGURE 21 KEY DEVELOPMENTS IN NGS-BASED RNA-SEQUENCING MARKET, 2019-2022
  • 11.3 MARKET SHARE ANALYSIS
    • FIGURE 22 NGS-BASED RNA-SEQUENCING MARKET SHARE, BY KEY PLAYER, 2021
    • TABLE 134 NGS-BASED RNA-SEQUENCING MARKET: DEGREE OF COMPETITION
  • 11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 11.5 COMPETITIVE LEADERSHIP MAPPING
    • 11.5.1 TERMINOLOGY/NOMENCLATURE
      • 11.5.1.1 Visionary leaders
      • 11.5.1.2 Innovators
      • 11.5.1.3 Dynamic differentiators
      • 11.5.1.4 Emerging companies
    • FIGURE 24 NGS-BASED RNA-SEQUENCING MARKET, COMPETITIVE LEADERSHIP MAPPING, 2021 (OVERALL MARKET)
    • FIGURE 25 NGS-BASED RNA-SEQUENCING MARKET, COMPETITIVE LEADERSHIP MAPPING, 2021 (SMES/START-UPS)
  • 11.6 COMPETITIVE SCENARIO
    • TABLE 135 NGS-BASED RNA-SEQUENCING MARKET: PRODUCT/SERVICE LAUNCHES
    • TABLE 136 NGS-BASED RNA-SEQUENCING MARKET: DEALS
    • TABLE 137 NGS-BASED RNA-SEQUENCING MARKET: OTHER DEVELOPMENTS

12 COMPANY PROFILES

  • (Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)**
  • 12.1 KEY PLAYERS
    • 12.1.1 ILLUMINA, INC.
    • TABLE 138 ILLUMINA, INC.: COMPANY OVERVIEW
    • FIGURE 26 ILLUMINA, INC.: COMPANY SNAPSHOT, 2021
    • TABLE 139 ILLUMINA, INC.: PRODUCT LAUNCHES
    • TABLE 140 ILLUMINA, INC.: DEALS
    • TABLE 141 ILLUMINA, INC.: OTHER DEVELOPMENTS
    • 12.1.2 QIAGEN N.V.
    • TABLE 142 QIAGEN N.V.: COMPANY OVERVIEW
    • FIGURE 27 QIAGEN N.V.: COMPANY SNAPSHOT, 2021
    • TABLE 143 QIAGEN N.V.: PRODUCT LAUNCHES & ENHANCEMENTS
    • TABLE 144 QIAGEN N.V.: DEALS
    • 12.1.3 PERKINELMER, INC.
    • TABLE 145 PERKINELMER, INC.: COMPANY OVERVIEW
    • FIGURE 28 PERKINELMER, INC.: COMPANY SNAPSHOT, 2021
    • TABLE 146 PERKINELMER, INC.: PRODUCT LAUNCHES
    • 12.1.4 EUROFINS SCIENTIFIC
    • TABLE 147 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
    • FIGURE 29 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT, 2021
    • TABLE 148 EUROFINS SCIENTIFIC: DEALS
    • 12.1.5 OXFORD NANOPORE TECHNOLOGIES
    • TABLE 149 OXFORD NANOPORE TECHNOLOGIES: COMPANY OVERVIEW
    • TABLE 150 OXFORD NANOPORE TECHNOLOGIES: PRODUCT LAUNCHES
    • TABLE 151 OXFORD NANOPORE TECHNOLOGIES: DEALS
    • TABLE 152 OXFORD NANOPORE TECHNOLOGIES: OTHER DEVELOPMENTS
    • 12.1.6 AGILENT TECHNOLOGIES, INC.
    • TABLE 153 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
    • FIGURE 30 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT, 2021
    • 12.1.7 BGI GROUP
    • TABLE 154 BGI GROUP: COMPANY OVERVIEW
    • TABLE 155 BGI GROUP: DEALS
    • 12.1.8 GENEWIZ (PART OF BROOKS AUTOMATION)
    • TABLE 156 GENEWIZ: COMPANY OVERVIEW
    • TABLE 157 GENEWIZ: SERVICES LAUNCHED
    • 12.1.9 HAMILTON COMPANY
    • TABLE 158 HAMILTON COMPANY: COMPANY OVERVIEW
    • 12.1.10 NUGEN TECHNOLOGIES (PART OF TECAN TRADING AG)
    • TABLE 159 NUGEN TECHNOLOGIES: COMPANY OVERVIEW
    • 12.1.11 PSOMAGEN (FORMERLY KNOWN AS MACROGEN)
    • TABLE 160 PSOMAGEN: COMPANY OVERVIEW
    • 12.1.12 F. HOFFMANN-LA ROCHE AG
    • TABLE 161 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
    • FIGURE 31 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT, 2021
    • TABLE 162 F. HOFFMANN-LA ROCHE AG: DEALS
    • 12.1.13 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 163 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW
    • FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT, 2021
    • TABLE 164 THERMO FISHER SCIENTIFIC, INC.: DEALS
    • 12.1.14 TAKARA BIO, INC.
    • TABLE 165 TAKARA BIO, INC.: COMPANY OVERVIEW
    • FIGURE 33 TAKARA BIO, INC.: COMPANY SNAPSHOT, 2021
    • 12.1.15 PACIFIC BIOSCIENCES
    • TABLE 166 PACIFIC BIOSCIENCES: COMPANY OVERVIEW
    • FIGURE 34 PACIFIC BIOSCIENCES: COMPANY SNAPSHOT, 2021
  • 12.2 OTHER PLAYERS
    • 12.2.1 ZYMO RESEARCH
    • 12.2.2 LUCIGEN CORPORATION
    • 12.2.3 GENOTYPIC TECHNOLOGY
    • 12.2.4 OXFORD GENE TECHNOLOGY (PART OF SYSMEX)
    • 12.2.5 BECTON, DICKINSON AND COMPANY
  • *Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)** might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS